Hong Qin Jiang

US Patent:

6445752, Sep 3, 2002

Filed:

Feb 12, 1999

Appl. No.:

09/248904

Inventors:

Hong Jiang - Montclair NJ
Paul L. Palmieri - New Providence NJ
Agesino Primatic, Jr. - Frenchtown NJ
Lesley J. Wu - Parsippany NJ
Liangkai Yu - New Providence NJ

Assignee:

Agere Systems Guardian Corp. - Miami Lakes FL

International Classification:

H04L 2714

US Classification:

375326, 375235

Abstract:

A phase tracker receives a signal component x and forms a phase- and gain-corrected signal z. In particular, the phase tracker performs a Hilbert transform of x to produce a quadrature phase component y to form the constellation defined by (x , y ). Consequently, phase rotation and gain adjustment are combined into a linear transform of the constellation defined by (x , y ). The linear transform z =x +y employs two coefficients and. The coefficients and of the linear transform are derived so as to provide an optimal solution according to minimum mean square error. Approximations to the coefficients and of the linear transform may be iteratively determined with a stochastic gradient method. Advantages of employing the phase- and gain-corrected signal z as an I-phase detection result of a demodulator include 1) the phase rotation and gain adjustment are combined into one operation, and 2) the a sine/cosine lookup table is not employed. Including both phase rotation and a gain adjustment may provide for better performance of the demodulator.

US Patent:

20030103988, Jun 5, 2003

Filed:

Oct 26, 1995

Appl. No.:

08/548595

Inventors:

LEONARD CHESS - SCARSDALE NY, US
RANDLE WARE - NEW YORK NY, US
HONG JIANG - NEW YORK NY, US
BENVENUTO PERNIS - BRONXVILLE NY, US

International Classification:

A61K039/395
A61K039/38
A01N001/02
A61K039/00

US Classification:

424/184100, 424/810000, 435/002000

Abstract:

The level of CD8 T cell cytotoxicity directed toward activated CD4 T cells expressing a specific T cell receptor V chain and a major histocompatibility complex class Ib molecule is assayed by contacting a sample containing CD8 T cells with the activated CD4 T cells for a determined period of time and determining the amount of activated CD4 T cell death during the time period. The level of CD8 T cell activity stimulated by the activated CD4 T cells is assayed by measuring lymphokine release from stimulated CD8 T cells or by determining the amount of cell surface molecules specifically expressed on stimulated CD8 T cells. An agent capable of stimulating or inhibiting CD8 T cells cytotoxicity toward the activated CD4 T cells will suppress or inhibit the suppression of an immune response mediated by the activated CD4 T cells, respectively.

US Patent:

20100267622, Oct 21, 2010

Filed:

Aug 24, 2009

Appl. No.:

12/583723

Inventors:

Hong Jiang - Fort Lee NJ, US
Leonard Chess - Scarsdale NY, US

International Classification:

A61K 38/02
C12N 5/0783
C12Q 1/02
A61P 37/00
A61P 37/06
A61P 31/04

US Classification:

514 24, 4353723, 514 11, 435 29

Abstract:

Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E* T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided.

US Patent:

20120029473, Feb 2, 2012

Filed:

Feb 9, 2010

Appl. No.:

13/144579

Inventors:

Hong Jiang - Fort Lee NJ, US
Leonard Chess - Scarsdale NY, US

International Classification:

A61M 37/00
A61P 37/06
A61K 39/395

US Classification:

604522, 4241431

Abstract:

A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.

US Patent:

20120183518, Jul 19, 2012

Filed:

Aug 24, 2010

Appl. No.:

13/392481

Inventors:

Hong Jiang - Fort Lee NJ, US
Leonard Chess - Scarsdale NY, US

International Classification:

A61K 35/14
C12Q 1/25
G01N 21/64
C12Q 1/02

US Classification:

424 9371, 435 29

Abstract:

A method of determining if a subject's CD8+ T-cells functionally recognize an HLA-E/Hsp60sp target structure comprising a) contacting a sample of the subject's CD8+ T-cells with a HLA-E+ cell loaded with Hsp60sp, b) quantifying proliferation of the contacted HLA-E+ cell, c) contacting a sample of the subject's CD8+ T-cells with a HLA-E+ cell which is loaded with a peptide which does not bind to HLA-E, d) quantifying proliferation of the HLA-E+ cell loaded with the peptide which does not bind to HLA-E following contact with the subject's CD8+ T-cells, e) comparing the proliferation quantified in step d) with the proliferation quantified in step b)

US Patent:

20220387553, Dec 8, 2022

Filed:

May 27, 2022

Appl. No.:

17/827089

Inventors:

- Cedar Knolls NJ, US
Hong Jiang - Fort Lee NJ, US

Assignee:

Avotres, Inc. - Cedar Knolls NJ

International Classification:

A61K 38/17
A61P 25/28
A61P 37/06
A61P 19/02
A61P 17/06
A61K 47/20
A61K 47/42
A61K 35/15

Abstract:

The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

US Patent:

20220378825, Dec 1, 2022

Filed:

May 27, 2022

Appl. No.:

17/827077

Inventors:

- Cedar Knolls NJ, US
Hong Jiang - Fort Lee NJ, US

Assignee:

Avotres, Inc. - Cedar Knolls NJ

International Classification:

A61K 35/15
A61K 38/17
A61K 38/38
A61K 31/10
C12N 5/0784

Abstract:

The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

US Patent:

20220378835, Dec 1, 2022

Filed:

May 27, 2022

Appl. No.:

17/827069

Inventors:

- Cedar Knolls NJ, US
Hong Jiang - Fort Lee NJ, US

Assignee:

Avotres, Inc. - Cedar Knolls NJ

International Classification:

A61K 35/17
C12N 5/0784
A61P 37/04

Abstract:

The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).